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Abstract
Many cells in mammals exist in the state of quiescence, which is characterized by reversible exit from the cell cycle.
Quiescent cells are widely reported to exhibit reduced size, nucleotide synthesis, and metabolic activity. Much lower
glycolytic rates have been reported in quiescent compared with proliferating lymphocytes. In contrast, we show here that
primary human fibroblasts continue to exhibit high metabolic rates when induced into quiescence via contact inhibition. By
monitoring isotope labeling through metabolic pathways and quantitatively identifying fluxes from the data, we show that
contact-inhibited fibroblasts utilize glucose in all branches of central carbon metabolism at rates similar to those of
proliferating cells, with greater overflow flux from the pentose phosphate pathway back to glycolysis. Inhibition of the
pentose phosphate pathway resulted in apoptosis preferentially in quiescent fibroblasts. By feeding the cells labeled
glutamine, we also detected a ‘‘backwards’’ flux in the tricarboxylic acid cycle from a-ketoglutarate to citrate that was
enhanced in contact-inhibited fibroblasts; this flux likely contributes to shuttling of NADPH from the mitochondrion to
cytosol for redox defense or fatty acid synthesis. The high metabolic activity of the fibroblasts was directed in part toward
breakdown and resynthesis of protein and lipid, and in part toward excretion of extracellular matrix proteins. Thus, reduced
metabolic activity is not a hallmark of the quiescent state. Quiescent fibroblasts, relieved of the biosynthetic requirements
associated with generating progeny, direct their metabolic activity to preservation of self integrity and alternative functions
beneficial to the organism as a whole.
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Introduction
Proliferating and quiescent cells are expected to have vastly
different metabolic needs. Proliferating cells must replicate the
entirety of their cellular contents in order to divide. As a result,
much of the metabolic energy in a proliferating cell is devoted to
synthesizing DNA, proteins, and lipids. Quiescent cells are relieved
of this massive metabolic requirement since they are not dividing
and, in several well-studied model systems, they decrease their
metabolic rates in accordance with their decreased proliferation
rates. Yeast cultures, for instance, enter stationary phase when
liquid cultures are grown to saturation in rich medium [1]. Within
this population, the quiescent yeast cells fail to accumulate mass
and volume [2], in part because quiescent yeast cells induce
autophagy, or self-cannibalism [3]. In addition, the overall
transcription rate is three to five times slower in stationary-phase
than in logarithmic-phase cultures [4], and protein synthesis is
reduced to approximately 0.3% of the rate in logarithmically
growing cultures [5]. Therefore, the quiescent cells within a
stationary-phase culture of yeast likely represent an example of a
quiescent cell that has significantly reduced its metabolic activity.
Lymphocytes also undergo a major metabolic shift upon
transitioning between proliferation and quiescence. Early studies
showed that lectin stimulation of lymphocytes led to increased
glucose uptake, and an increased rate of glycolysis and pentose
phosphate pathway (PPP) activities [6,7]. More recent experiments
have focused on a murine pro-B cell lymphoid cell line, FL5.12,
that proliferates in response to the cytokine interleukin IL-3 [8].
IL-3 stimulation results in an 8-fold increased glycolytic flux. IL-3
also induces the cells to consume less oxygen per glucose
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away from oxidative toward glycolytic metabolism. For human
peripheral blood T lymphocytes, stimulation resulted in a 30-fold
increase in glycolysis [9]; for thymocytes, the increase was 50-fold
[10]. These differences in quiescent and proliferating lymphocytes
have played a pivotal role in our understanding of the quiescent
state, and experiments with lymphocytes as a model system have
been important contributors to the development of the idea that
quiescence is characterized by decreased metabolic activity.
Lymphocytes, however, are relatively unique among mammalian
cells in having primarily a ‘‘watching and waiting’’ function when
quiescent and performing much of their physiological role only
after activation.
Our studies focus on newborn dermal fibroblasts as a model
system of quiescence [11–13]. In vitro, primary fibroblasts isolated
directly from newborn foreskin can be induced into reversible
quiescence by serum withdrawal or contact inhibition. Unlike
most primary cells, fibroblasts remain healthy in culture in a
quiescent state for as long as 30 d with little apoptosis or
senescence, and can then re-enter the cell cycle [13]. In vivo,
quiescent fibroblasts are central to normal physiology as the
primary synthesizers of extracellular matrix necessary for the
formation of cellular tissues. In response to a wound, fibroblasts
enter the cell cycle from quiescence, proliferate, and secrete a
collagen-rich extracellular matrix [14], pro-angiogenesis factors
that recruit new blood vessels [13], and other molecules that
facilitate the wound healing response [15]. A better understanding
of the transition between proliferation and quiescence in
fibroblasts would have broad implications for physiology and
medicine. Scarring and fibrosis result from excessive fibroblast
proliferation and secretion of extracellular matrix during and after
wound healing [16,17]. Additionally, tumors may contain
quiescent cells that contribute to cancer dormancy [18,19]. Thus,
a better understanding of the transition between proliferation and
quiescence, including the metabolic changes that occur, could
have implications for a wide range of medical conditions.
The emerging field of metabolomics promises to augment our
understanding of mammalian cell physiology through the systems-
level characterization of cell-wide metabolite concentrations and
fluxes. Using liquid chromatography–triple quadrupole mass
spectrometry, we have developed a methodology for monitoring
the pool size and turnover of a large number of metabolites
simultaneously [20–22]. Here we apply metabolomic technology,
flux analysis, and biochemical assays to investigate metabolic
changes after primary dermal fibroblasts enter quiescence. We
discovered that contact-inhibited primary fibroblasts remain
highly metabolically active while adjusting their metabolic
emphasis to produce NADPH, steadily renew their proteins and
lipids, and enhance secretion of specific extracellular matrix
proteins.
Results
A Model for Cellular Quiescence in Primary Fibroblasts
We have developed a model system that allows us to monitor
metabolic differences between proliferating and quiescent cells.
Primary dermal fibroblasts were expanded and analyzed while
actively proliferating, after 1 wk of growth to confluence (contact-
inhibited for 7 d [CI7]), after 2 wk of confluence (contact-inhibited
for 14 d [CI14]), or after 2 wk of confluence with serum
concentrations decreased for the final week from 10% to 0.1%
(contact-inhibited for 14 d and serum-starved for 7 d [CI14SS7]).
Alternatively, fibroblasts were plated sparsely so that they did not
touch each other and induced into quiescence by serum starvation
and monitored after 4 d (serum-starved for 4 d [SS4]) or 7 d
(serum-starved for 7 d [SS7]). In quiescent fibroblasts, the fraction
of cells with 2N DNA content increased so that 80% or more of
the cells were in the G0/G1 phase of the cell cycle (Figure 1A). The
fraction of cells in S phase was significantly reduced, indicating
that very few cells were actively dividing under these conditions. In
both contact-inhibited and serum-starved fibroblasts, levels of the
cyclin-dependent kinase inhibitor p27
Kip1 were upregulated, as
expected for cells that entered quiescence (Figure 1B) [23]. In
addition, staining with pyronin Y for total RNA indicated that the
fraction of cells with low pyronin Y, interpreted as cells in G0 [24],
increased in fibroblasts induced into quiescence by all of these
methods (Figure 1C). Pyronin Y labeling data indicate that in the
contact-inhibited and serum-starved cell populations investigated
as quiescence models, approximately 60%–75% of the cells are in
G0 and most of the remainder are in G1.
Rapid Glycolytic Flux in Proliferating and Quiescent
Fibroblasts
Previous studies have reported that lymphocytes induced to exit
the cell cycle in response to mitogen withdrawal exhibit decreased
glycolytic activity [8]. We used several methods to assess metabolic
rates in proliferating, CI7, CI14, and CI14SS7 cells. We
monitored the rates at which glucose and glutamine were
consumed from the medium, and lactate and glutamate were
secreted into the medium. As shown in Figure 2A, the rate of
glucose consumption was approximately 2-fold lower in the
contact-inhibited than in the proliferating fibroblasts. Lactate
secretion decreased less than 2-fold with contact inhibition alone,
and roughly 2-fold with additional serum deprivation. Glucose
consumption actually slightly increased in fibroblasts induced into
quiescence by serum starvation (without contact inhibition) for 4
or 7 d (Figure S1). We also monitored metabolic rates in
fibroblasts cultured in medium conditions containing physiological
levels of glucose and glutamine (1 g/l glucose and 0.7 mM
glutamine compared with 4.5 g/l glucose and 4 mM glutamine in
Dulbecco’s Modified Eagle Medium [DMEM]) [25,26]. Metabolic
rates were somewhat lower in proliferating fibroblasts in these low
glucose/low glutamine conditions compared with proliferating
Author Summary
Many cells in the human body are in a reversible state of
quiescence, where they have exited the cell cycle but
retain the capacity to re-enter it and divide again. Previous
experiments in lymphocytes had suggested that quiescent
cells reduce their glucose uptake and metabolic rate. In
our studies, we have investigated the metabolism of
fibroblasts, cells found in connective tissue and skin. Using
‘‘metabolomics’’ to monitor flux through metabolic
pathways, we discovered that fibroblasts remain highly
metabolically active even though they are not dividing.
They degrade and resynthesize protein and fatty acid, and
secrete large amounts of protein into the extracellular
environment. Despite our expectation that quiescent cells
would not have a high demand for nucleotide biosynthe-
sis, we found that they do divert glucose to the pentose
phosphate pathway, presumably to generate NADPH. The
NADPH created may help the quiescent fibroblasts to
detoxify free radicals or to synthesize fatty acids. Experi-
ments in which we inhibited the pentose phosphate
pathway resulted in increased apoptosis in quiescent cells,
suggesting a possible strategy for selectively killing
nondividing cells.
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PLoS Biology | www.plosbiology.org 2 October 2010 | Volume 8 | Issue 10 | e1000514Figure 1. Model system of proliferating and quiescent fibroblasts. (A) Proliferating (P), CI7, CI14, and CI14SS7 fibroblasts were stained with PI
and analyzed for cell cycle distribution with flow cytometry. The fraction of cells in G0/G1 increased in quiescent cells. Images of cells in different
proliferative states are shown below. (B) Lysates from fibroblasts induced into quiescence by contact inhibition or serum starvation were collected
over a time course and analyzed by immunoblotting with an antibody to p27
Kip1. p27
Kip1 levels were induced in cells made quiescent by either
antiproliferative signal. (C) Proliferating and quiescent fibroblasts were stained with pyronin Y and Hoechst 33342 and analyzed by flow cytometry
(lower panels). The fraction of cells with low pyronin Y content increased in fibroblasts induced into quiescence by multiple methods (upper panel).
doi:10.1371/journal.pbio.1000514.g001
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cultured in these conditions exhibited consumption and excretion
rates approximately half that of proliferating fibroblasts. Our
finding that glycolytic rates are similar within a factor of two in
proliferating and quiescent fibroblasts is surprising given that
changes in glycolytic rate have been shown to mirror changes in
proliferative rate in multiple model systems [8–10]. Indeed, while
there is a dramatic decrease in the fraction of cells in the
proliferative cell cycle, even the CI14SS7 condition resulted in
only a 2-fold change in glucose consumption, much less than
reported in other systems. Thus, decreased metabolic activity is
not a universal hallmark of quiescence.
To further assess glycolytic rates in proliferating and contact-
inhibited fibroblasts, we monitored the steady state pool sizes of
glycolytic intermediates using liquid chromatography coupled to
tandem mass spectrometry [20–22]. In total, we monitored the
levels of 172 metabolites, 62 of which gave signals above
background in proliferating, CI7, and CI14 fibroblasts. Metabolite
levels were normalized per microgram of protein in cells plated at
the same density because quiescent fibroblasts are smaller and
contain less protein per cell than proliferating fibroblasts (E. M.
Haley, A. L.-M., and H. A. C., unpublished data). The ratio of
metabolite levels in the contact-inhibited (CI7 and CI14) to
proliferating fibroblasts was determined for each metabolite. Some
metabolites were present at consistently higher levels in prolifer-
ating fibroblasts, while others were enriched in contact-inhibited
fibroblasts, although the magnitude of these changes in metabolite
levels was generally modest (Figure S2).
Levels of five glycolytic intermediates and pentose-5-phosphate
(a combination of ribose-5-phosphate, ribulose-5-phosphate, and
xylulose-5-phosphate, which could not be reliably differentiated in
our liquid chromatography–tandem mass spectrometry [LC-MS/
MS] method) are shown in Figure 2B. No statistically significant
differences were observed in the levels of glycolytic intermediates
between contact-inhibited (CI7 or CI14) and proliferating
fibroblasts at a false discovery rate of 0.05. Some glycolytic
metabolites were present at lower levels in contact-inhibited,
serum-deprived (CI14SS7) fibroblasts. Thus, the transition be-
tween proliferation and quiescence induced by contact inhibition
alone has little effect on the pool sizes of glycolytic metabolites in
primary fibroblasts. While pool sizes are not a direct indication of
changes in flux, the constant levels of glycolytic metabolites in
proliferating, CI7, and CI14 fibroblasts are consistent with our
finding that there is little change in the rate of glucose uptake or
lactate secretion among fibroblasts in these different states.
To more directly assess the rate of flux through glycolytic
pathways, we incubated fibroblasts with [U-
13C]-glucose and
determined how quickly the label was incorporated into glycolytic
intermediates (Figure 2C). For hexose phosphate (a combination of
glucose-1-phosphate, glucose-6-phosphate, and fructose-6-phos-
phate), fructose-1,6-bisphosphate (FBP), dihydroxyacetone phos-
phate (DHAP), and phosphoenolpyruvate, the unlabeled pools of
intermediates were converted into fully
13C-labeled intermediates
at a similar rate in proliferating, CI7, and CI14 fibroblasts.
We also developed a computational model based on ordinary
differential equations (ODEs) of central carbon metabolism for the
proliferating,CI7,CI14,andCI14SS7fibroblasts.TheODEsinthe
model quantify the isotope labeling dynamics of the relevant
metabolites after switching into
13C-labeled carbon sources (Figure
S3). Model parameters (i.e., metabolic fluxes and some unmeasured
pool sizes) were identified by fitting all of the available laboratory
data (labeling dynamics, pseudo-steady-state labeling patterns,
measured pool sizes, and uptake and excretion rates). This
systems-level approach enabled quantitation of flux through
Figure 2. Glycolytic rates are similar in proliferating and
quiescent fibroblasts. (A) The amount of glucose, lactate, glutamine,
and glutamate were measured in conditioned medium from prolifer-
ating (P), CI7, CI14, and CI14SS7 cells. Data are from three experiments
with five replicates at each time point, and error bars indicate standard
error. (B) Metabolites were extracted from cells in different proliferative
states, and the levels of specific metabolites were quantified using mass
spectrometry. Metabolite levels in individual samples were normalized
to protein content at the time of harvest. Means from four experiments,
each containing 4–5 replicates, are shown. Error bars indicate standard
error. With a false discovery rate of 0.05, none of the metabolite levels
are different between the proliferating, CI7, and CI14 cells. (C) Isotope
labeling dynamics of glycolysis in proliferating, CI7, and CI14 fibroblasts.
Medium was changed to [U-
13C]-glucose at time zero, and the fraction
of each metabolite that is
13C-labeled was determined at the indicated
times after switching to labeled medium. Data are pooled from five
experiments, and error bars indicate standard deviations. 3PG, 3-
phosphoglycerate; Hexose-P, hexose phosphate; Pentose-P, pentose
phosphate; PEP, phosphoenolpyruvate.
doi:10.1371/journal.pbio.1000514.g002
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CI14SS7 fibroblasts (Figure S4 and Table S1). For glycolysis, the
inferred fluxes from hexose phosphate to FBP, and from DHAP to
3-phosphoglycerate, were similar in proliferating, CI7, and CI14
conditions (Figures 3 and S4 and Table S1; see Materials and
Methods for information regarding statistical significance). In
CI14SS7 fibroblasts, hexose phosphate–to-FBP and DHAP-to–3-
phosphoglycerate fluxes are approximately half those in the other
conditions (Figure S4 and Table S1), consistent with an approxi-
mately 2-fold reduction in glucose consumption. We conclude that
glucose consumption and lactate excretion proceed rapidly in
fibroblasts induced into quiescence by contact inhibition.
Quiescent Fibroblasts Exhibit High PPP Activity
The PPP produces ribose-5-phosphate, needed for the biosynthe-
sis of nucleotides, and NADPH, which can be used as a cofactor for
the biosynthesis of macromolecules including fatty acids. We
anticipated that proliferating cells would have higher demands for
both ribose-5-phosphate and NADPH than quiescent cells, and thus
higher PPP flux. Surprisingly, the pentose phosphate pool
incorporated
13C label very rapidly in proliferating, CI7, and CI14
fibroblasts when the cells were incubated with labeled [U-
13C]-
glucose (Figure 4A). Indeed, according to our computational model,
hexose phosphate–to–pentose phosphate flux was actually slightly
higher in contact-inhibited (both CI7 and CI14) fibroblasts than in
proliferating fibroblasts (though the effect was not statistically
significant). Additional serum deprivation only slightly decreased
oxidative PPP flux, with the oxidative PPP flux–to–glycolytic flux
ratio highest in CI14SS7 fibroblasts. Thus, the oxidative PPP is
actively utilized in both proliferating and quiescent cells.
We anticipated that ribose generated from the PPP would be
incorporated into nucleotide triphosphates more rapidly in
proliferating than quiescent cells because of their increased need
for nucleotide triphosphates for RNA and DNA synthesis. Indeed,
in proliferating fibroblasts, ATP and UTP with labeled ribose rings
accumulate more rapidly in proliferating fibroblasts (Figure 4A).
The results confirm that biosynthesis of nucleotides is more rapid
in the proliferating cells.
Given that quiescent fibroblasts do not commit ribose phosphate
to nucleotide biosynthesis, we reasoned that quiescent cells might
recycle ribose phosphate back to glycolytic intermediates through
the non-oxidative branch of the PPP. To test this hypothesis, we
monitored the ratio of 16
13C-lactate to 26
13C-lactate after
incubating the cells with [1, 2-
13C]-glucose. As previously described
[27], 16
13C-lactate is formed when glucose is metabolized through
the oxidative portion of the PPP to ribulose-5-phosphate. In this
pathway, glucose molecules lose one
13C atom in the form of CO2,
and are then returned to glycolysis through the non-oxidative
branch of the PPP (Figure 4B). 26
13C-lactate is formed by the
canonical glycolysis pathway from glucose to lactate. The ratio of
16
13C-lactate to 26
13C-lactate provides an indication of the extent
to which the non-oxidative branch of the PPP is utilized. This ratio
is significantly higher in CI7 than proliferating fibroblasts, and even
higher in CI14 fibroblasts (Figure 4C).
As another indication of the rate of flux through the non-
oxidative branch of the PPP, we monitored labeling of
sedoheptulose-7-phosphate, a metabolic intermediate in the non-
oxidative PPP. Sedoheptulose-7-phosphate is labeled rapidly in
CI7 and CI14 but not proliferating fibroblasts fed [U-
13C]-glucose
(Figure 4A), indicating higher flux through the non-oxidative
branch of the PPP in quiescent cells. Our systems-level flux
analysis confirmed increased flux from ribose phosphate back to
glycolysis in contact-inhibited compared with proliferating fibro-
blasts (Figures 3 and S4 and Table S1). Thus, ribose phosphate
generated from the PPP is utilized for nucleotide biosynthesis in
proliferating fibroblasts but is recycled back to glycolytic
intermediates in quiescent fibroblasts.
Functional Importance of the PPP
To investigate the mechanistic basis for the high PPP flux in
quiescence fibroblasts, we monitored protein levels of two key
enzymes in the PPP, both of which generate NADPH: glucose-6-
phosphate dehydrogenase (G6PD) and 6-phosphogluconate dehy-
drogenase (PGD). Protein levels of both G6PD and PGD were
elevated in fibroblasts induced into quiescence by either contact
inhibition or serum starvation in comparison to proliferating
fibroblasts (Figure 5A). These results suggest that contact-inhibited
and serum-starved fibroblasts may activate a program that results
in increased levels of PPP enzymes.
Both proliferating and quiescent fibroblasts generate NADPH
through the PPP. The NADPH may be used for biosynthesis or to
regenerate the reduced forms of glutathione or thioredoxin. We
Figure 3. Comparison of central metabolic fluxes in proliferat-
ing and CI14 fibroblasts. Fluxes were derived by computational
integration of all available experimental data within a systems-level,
flux-balanced metabolic model. Arrow size indicates the magnitude of
the flux in CI14 fibroblasts. Color indicates relative rates compared to
proliferating fibroblasts; red indicates higher flux in CI14 fibroblasts and
green indicates higher flux in proliferating fibroblasts. While the ribose
phosphate–to-UTP flux is mostly faster (within the 1,000 identified
solutions) for proliferating than quiescent fibroblasts, its distributions
do overlap across different proliferative states, so our stringent
condition for different rates is not met in this particular case (see
Materials and Methods). aKG, a-ketoglutarate; Hexose-P, hexose
phosphate; OAA, oxaloacetate; Pentose-P, pentose phosphate; PEP,
phosphoenolpyruvate.
doi:10.1371/journal.pbio.1000514.g003
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respectively) in proliferating, CI7, CI14, and CI14SS7 fibroblasts.
As shown in Figure 5B and 5C, GSH was slightly increased, and
the ratio of GSH to GSSG significantly enhanced, in quiescent
(CI7, CI14, and CI14SS7) compared with proliferating fibroblasts.
The results are consistent with a model in which quiescent
fibroblasts upregulate NADPH production in part to ensure
adequate GSH as protection against free radicals [28].
We then tested the functional importance of the PPP in
quiescent and proliferating fibroblasts. We incubated proliferating
or CI14 fibroblasts with dehydroepiandrosterone (DHEA), a small
molecule inhibitor of the PPP [29,30] for 4 d and monitored the
fraction of cells that were dead with propidium iodide (PI) labeling
followed by flow cytometry. We discovered that the contact-
inhibited fibroblasts exhibited a statistically significant increase in
cell death compared with the proliferating fibroblasts from DHEA
Figure 4. The PPP is active in quiescent fibroblasts. (A) Isotope labeling dynamics in the PPP for proliferating (P), CI7, and CI14 fibroblasts. The
fraction of fully labeled hexose phosphate, pentose phosphate, or sedoheptulose-7-phosphate after addition of [U-
13C]-glucose is plotted for cells in
each condition at each time point. Similarly, the fraction of ATP and UTP with five
13C atoms is plotted. The 56
13C-ATP and 56
13C-UTP are uniformly
labeled in their ribose portion and unlabeled in the base portion, as confirmed by tandem mass spectrometry analysis. Data are pooled from five
experiments, and error bars indicate standard deviation. -P, phosphate. (B) Schematic diagram of lactate labeling from [1, 2-
13C]-glucose. [1, 2-
13C]-
glucose is converted into 26
13C-lactate through the canonical glycolysis pathway and 16
13C-lactate through the PPP. (C) Fibroblasts in different
proliferative conditions were incubated with [1, 2-
13C]-glucose for 4 h. Levels of 16
13C-lactate and 26
13C-lactate were monitored with mass
spectrometry. The ratio of 16
13C-lactate to 26
13C-lactate is plotted for fibroblasts in each condition. Means 6 one standard error (n=4) are shown.
Asterisks indicate p-value,0.01 (proliferating versus CI7, p=0.006, and proliferating versus CI14 fibroblasts p=0.002 by Student’s t test).
doi:10.1371/journal.pbio.1000514.g004
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This result is particularly impressive given that almost all known
metabolic inhibitors and cytotoxins preferentially kill proliferating
cells [18,31,32]. Assaying for caspase-3/7 activity revealed that the
mechanism of DHEA-induced cell death in the quiescent
fibroblasts is via apoptosis (Figure 6B). The apoptosis-inducing
effect of DHEA was significantly stronger in fibroblasts that were
confluent for 11 d than in proliferating fibroblasts, and yet
stronger in fibroblasts serum-starved for 7 d in the absence of
contact inhibition.
Truncated Tricarboxylic Acid Cycle in Proliferating but
Not Quiescent Fibroblasts
Previous studies concluded that proliferating lymphocytes
actively utilize glycolytic pathways to generate ATP while quiescent
lymphocytesgenerateenergyvia aninfluxoffattyacidsandproteins
that are metabolized through the tricarboxylic acid (TCA) cycle [8].
To investigate TCA cycle usage, we monitored metabolite labeling
through the TCA cycle after addition of [U-
13C]-glucose, [3-
13C]-
glucose or [U-
13C]-glutamine in proliferating, CI7, and CI14
Figure 5. PPP enzymes are induced and the fraction of GSH is
enhanced in quiescent fibroblasts. (A) Protein levels of G6PD and
PGD, both of which generate NADPH, were monitored in proliferating
(P) and quiescent fibroblasts by immunoblotting. GAPDH was
monitored as a loading control. (B) Total GSH and GSSG content of
proliferating, CI7, CI14, and CI14SS7. Data represent one experiment
performed in duplicate, and error bars indicate standard deviation. (C)
The ratio of GSH to GSSG was calculated using the data from (B).
doi:10.1371/journal.pbio.1000514.g005
Figure 6. The PPP contributes to the survival of quiescent
fibroblasts. (A) Proliferating (P) or CI14 fibroblasts were treated with
DMSO control, 100 mM DHEA, or 250 mM DHEA for 4 d. Cells were
incubated with PI and analyzed by flow cytometry. Data are from four
independent experiments; error bars indicate standard error. For CI14
versus proliferating with no treatment, p=0.113. For CI14 versus
proliferating with 100 mM DHEA, p=0.0012. For CI14 versus proliferat-
ing with 250 mM DHEA, p=0.0011. Asterisks indicate statistical sig-
nificance of p,0.01. (B) Proliferating fibroblasts, fibroblasts contact-
inhibited for 11 d (CI11), or SS7 fibroblasts were treated with ethanol
vehicle control or varying amounts of DHEA dissolved in ethanol for
4 d. Cells were analyzed for caspase-3/7 activity by monitoring
luminescence emission of a caspase-3/7 substrate. Data were normal-
ized to the vehicle control. For proliferating versus CI11 cells, results are
an average of four experiments with 2–3 replicates; error bars represent
standard error and asterisks indicate statistical significance of p,0.05.
Normalized caspase-3/7 activity in CI11 and proliferating cells was
statistically significantly different at all doses except 100 mM. For
proliferating versus SS7 cells, data represent three experiments with
three replicates in each. Normalized caspase activity in SS7 and
proliferating cells was statistically significantly different at all doses.
doi:10.1371/journal.pbio.1000514.g006
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fibroblasts incorporate twocarbonunitsfrom glucose intocitrate via
acetyl-CoA at comparable rates. In CI7 and CI14 fibroblasts, the
labeled carbons progress through the TCA cycle to form 26
13C-a-
ketoglutarate, as expected. In proliferating fibroblasts, however,
there is a substantial decrease in the transmission of labeled carbons
from citrate to a-ketoglutarate, succinate, and malate. Experiments
using [U-
13C]-glutamine further support the truncation of the TCA
cycle (Figure8).Whilecarbonfrom glutamineeffectivelytransverses
the left side of the TCA cycle in the standard clockwise direction to
yield 46
13C-citrate in both proliferating and quiescent fibroblasts,
subsequent formation of 36
13C-a-ketoglutarate by isocitrate
dehydrogenase hardly occurs in proliferating fibroblasts. The
decreased flux from citrate to a-ketoglutarate in proliferating
fibroblasts was confirmed via our systems-level flux identification
(Figures 3 and S4 and Table S1).
When carbon skeletons are removed from the TCA cycle for the
synthesis of macromolecular precursors including amino acids,
other long carbon skeletons are needed to replace them. This
anaplerotic refilling should be especially important for proliferat-
ing fibroblasts since their TCA cycle activity is truncated at citrate.
The major anaplerotic reaction from glycolysis involves the
carboxylation of pyruvate to form oxaloacetate. This reaction
can be monitored by feeding cells [3-
13C]-glucose and monitoring
the fraction of citrate or malate with label, since the
13C is retained
only when the anaplerotic reaction via pyruvate carboxylase is
utilized. Surprisingly, the ratios of 16
13C-citrate to unlabeled
citrate and/or 16
13C-malate to unlabeled malate were signifi-
cantly increased in CI7, CI14, and CI14SS7 fibroblasts compared
with proliferating fibroblasts (Table S2). In addition, quantitative
flux analysis revealed that anaplerotic flux from pyruvate to
oxaloacetate is elevated in CI7, CI14, and CI14SS7 compared
with proliferating fibroblasts (Figure S4 and Table S1), while the
flux from pyruvate to acetyl-CoA is lower in CI14 and CI14SS7
fibroblasts than in proliferating fibroblasts. Thus, contact inhibi-
tion was associated with both an increase in canonical TCA cycle
activity past citrate, and an increase in anaplerotic TCA cycle flux
from pyruvate to oxaloacetate. Proliferating fibroblasts, in
contrast, seem unlikely to have sufficient carbon skeletons from
glucose for the production of proteogenic amino acids not present
in the cell growth medium.
Glutamine Is the Preferred Anaplerotic Source in
Proliferating Fibroblasts
We hypothesized that proliferating fibroblasts rely on another
source for carbon skeletons. Supplementation with glutamine has
been shown to be necessary for cultured cells, especially actively
proliferating cells [33–36]. Accordingly, we monitored the rate of
Figure 7. A truncated TCA cycle in proliferating but not contact-inhibited fibroblasts. Proliferating (P), CI7, and CI14 fibroblasts were
switched from unlabeled to [U-
13C]-glucose at time zero. The graphs show the fractional incorporation of
13C into the indicated metabolites over
time. Data represent averages from three experiments, and error bars indicate standard deviation. Note the minimal labeling of a-ketoglutarate and
succinate in the proliferating cells.
doi:10.1371/journal.pbio.1000514.g007
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PLoS Biology | www.plosbiology.org 8 October 2010 | Volume 8 | Issue 10 | e1000514Figure 8. Glutamine drives both clockwise and counterclockwise flux through the TCA cycle. (A) Proliferating (P), CI7, or CI14 fibroblasts
were incubated with [U-
13C]-glutamine. Metabolites were harvested and their extent of labeling measured by LC-MS/MS. a-Ketoglutarate in the TCA
cycle can be converted to succinate in the clockwise (or ‘‘forward’’) direction or converted to citrate in the counterclockwise (or ‘‘reverse’’) direction.
The only known route to 56
13C-citrate is via this ‘‘reverse’’ flux from a-ketoglutarate. 56
13C-Citrate can then be converted to 36
13C-malate by ATP-
citrate lyase to produce acetyl-CoA to drive fatty acid biosynthesis. Data represent the average of four experiments. Error bars indicate standard
deviations. (B) IDH1 is upregulated at the transcript and protein level in quiescent fibroblasts. Transcript levels of IDH1 were monitored in two
independent experiments (indicated with subscripts) of proliferating, CI7, and CI14 fibroblasts by microarray (left panel). Data are shown in a
heatmap format with elevated expression in quiescent cells shown in red and decreased expression in quiescent cells in green. Results are shown for
multiple isocitrate dehydrogenase isozymes. Protein levels for IDH1, a metabolic enzyme that catalyzes the conversion of isocitrate to a-ketoglutarate
and thereby generates NADPH, were monitored by immunoblotting (right panel). GAPDH was monitored as a loading control. (C) Proliferating, CI7,
CI14, and CI14SS7 fibroblasts were incubated with [U-
14C]-glutamine for 24 h. Fatty acids were extracted, and
14C incorporation was determined by
scintillation counting and normalized for the amount of protein present. Error bars indicate standard error. p-Values were determined with the
Student’s t test, and asterisks indicate p,0.05. For CI7 versus proliferating, p=0.0025; for CI14 versus proliferating, p=0.018; for CI14SS7 versus
proliferating, p=0.0001.
doi:10.1371/journal.pbio.1000514.g008
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fibroblasts (Figures 2A and S1). CI7, CI14, and CI14SS7 fibroblasts
consume approximately half as much glutamine per microgram of
protein as proliferating fibroblasts. CI7 and CI14 fibroblasts secrete
glutamate at a lower rate compared with proliferating fibroblasts,
and CI14SS7 fibroblasts secrete glutamate at a lower rate than CI7
or CI14 fibroblasts. SS4 and SS7 fibroblasts, on the other hand,
consume glutamine and secrete glutamate at a faster rate than
proliferating fibroblasts (Figure S1). The relative rate of glutamine
consumption in proliferating versus CI14 fibroblasts in low glucose/
low glutamine conditions is similar to that in standard medium. As
shown in Figure 8, incubation of proliferating, CI7, and CI14
fibroblasts with [U-
13C]-glutamine results in rapid labeling of
glutamate,a-ketoglutarate,succinate,malate,andcitrate,indicating
that glutamine is used by both proliferating and contact-inhibited
fibroblasts for TCA cycle anaplerosis. Since very few glucose
carbons are incorporated into the TCA cycle in proliferating
fibroblasts, glutamine may serve as the major anaplerotic precursor
in proliferating fibroblasts [36–39].
Glutamine Labeling Reveals ‘‘Reverse’’ TCA Flux
[U-
13C]-glutamine is converted into 56
13C-glutamate and
subsequently to 56
13C-a-ketoglutarate. 56
13C-a-ketoglutarate
can proceed through the TCA cycle in the forward direction to
generate 46
13C-succinate, or, alternatively, it can be reductively
carboxylated to 56
13C-citrate using NADPH as the electron
source [40,41]. As shown in Figure 8A, introduction of [U-
13C]-
glutamine led to conversion of approximately 15% of the citrate to
the 56
13C form in proliferating, CI7, and CI14 fibroblasts by 8 h,
with more rapid labeling in contact-inhibited fibroblasts. These
results support a model in which there is both forward and reverse
flux between citrate and a-ketoglutarate, with greater flux in both
directions in contact-inhibited than in proliferating fibroblasts
(Figures 3 and S4 and Table S1). The forward and reverse flux
likely occur in different compartments, with a-ketoglutarate
reductively carboxylated by isocitrate dehydrogenase 2 (IDH2)
in the mitochondrion, and the resulting citrate reconverted to a-
ketoglutarate by IDH1 in the cytosol [42]. As both IDH1 and
IDH2 use NADP(H) as their redox cofactor, the net effect is
transfer of high energy electrons in the form of NADPH to the
cytosol. Consistent with greater flux through this pathway in
contact-inhibited fibroblasts, IDH1 protein is increased by contact
inhibition at the transcript and protein levels (Figure 8C). Thus,
two major pathways to cytosolic NADPH, the PPP and the IDH2/
IDH1 shuttle, are upregulated at both the protein and flux level in
contact-inhibited fibroblasts.
Fatty Acid and Protein Degradation and Resynthesis
Occur Rapidly in Proliferating and Quiescent Fibroblasts
Quiescent cells do not dilute out older macromolecules,
organelles, or membranes with cell division, and thus may be
more dependent than proliferating cells on mechanisms to break
down and resynthesize membrane components and macromole-
cules. Our data are consistent with increased fatty acid
degradation in contact-inhibited fibroblasts. Carnitine, a metab-
olite involved in the transport of fatty acids from the cytoplasm to
the mitochondria during fatty acid degradation, is present at
higher levels in CI7 and CI14 fibroblasts than in proliferating
fibroblasts (Figure S2). Also, quantitative flux identification
revealed, based on long-term labeling patterns of citrate, increased
fatty acid breakdown in CI7 and CI14 fibroblasts, but lower rates
of fatty acid breakdown in CI14SS7 fibroblasts (Figures 3 and S4
and Table S1).
The enhanced rate of fatty acid degradation in contact-inhibited
fibroblasts seems to be enabling fatty acid biosynthesis to occur at
a similar rate in proliferating and contact-inhibited fibroblasts.
During fatty acid synthesis, citrate is transported out of the
mitochondria to the cytoplasm, where it is broken down by ATP
citrate lyase into oxaloacetate and acetyl-CoA used in fatty acid
biosynthesis. ATP citrate lyase activity can be monitored based on
the conversion of 56
13C-citrate to 26
13C-acetyl-CoA and 36
13C-
oxaloacetate (measured as 36
13C-malate). As shown in Figure 8A,
36
13C-malate is produced similarly in proliferating, CI7, and
CI14 cells, consistent with fibroblasts in all of these states being
actively engaged in fatty acid biosynthesis. To more directly assess
fatty acid biosynthesis in proliferating and quiescent fibroblasts, we
extracted lipids from proliferating, CI7, CI14, and CI14SS7
fibroblasts fed [U-
14C]-glutamine. The contribution of carbons to
fatty acids from glutamine was significantly higher in all of the
quiescent fibroblasts compared with the proliferating fibroblasts
(Figure 8B), consistent with higher ‘‘backwards’’ flux from a-
ketoglutarate to citrate (Figures 3 and S4 and Table S1). The
higher levels of fatty acid synthesis in contact-inhibited fibroblasts
may contribute to the maintenance of membrane integrity, and
may also provide a major sink for cytosolic NADPH.
Similarly, our results suggest that contact-inhibited fibroblasts
may also be actively degrading existing protein, and thus
resynthesizing protein to replace the degraded proteins. As shown
in Figure 9, the fraction of glutamate that is labeled in fibroblasts
under all conditions increases rapidly after switching cells into
[U-
13C]-glutamine and then drops off in CI7 and CI14 fibroblasts,
but not in proliferating fibroblasts. This decline in the fraction of
glutamate molecules with five labeled carbons corresponds to an
increase in the fraction of unlabeled glutamate. One possible
explanation for these data is a breakdown of unlabeled proteins
and release of free amino acids into the glutamate pool. These
results are in agreement with our quantitative flux analysis: protein
synthesis rates are similar across all conditions [43,44] (Figures 3
and S4 and Table S1). Protein synthesis rates in the best-fit model
are 3.3 nmol/min/mg protein for proliferating fibroblasts,
4.3 nmol/min/mg protein for CI7 fibroblasts, 4.1 nmol/min/mg
protein for CI14 fibroblasts, and 2.9 nmol/min/mg protein for
CI14SS7 fibroblasts. Thus, one reason for the active metabolism
observed in contact-inhibited fibroblasts may be to rebuild and
thus refresh their lipid and protein contents.
Figure 9. Labeled glutamate levels decrease with time after
switching into [U-
13C]-glutamine in CI7 and CI14 but not
proliferating fibroblasts. Proliferating (P), CI7, or CI14 fibroblasts
were switched from unlabeled medium to medium containing [U-
13C]-
glutamine, and the fraction of fully labeled glutamate (left plot) and
unlabeled glutamate (right plot) was determined over time. Results are
an average of four experiments, and error bars indicate standard
deviations.
doi:10.1371/journal.pbio.1000514.g009
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Extracellular Matrix Proteins
The high metabolic activity of quiescent fibroblasts might also
be partially explained by their synthesis and secretion of
extracellular matrix molecules needed for the structural integrity
of tissue. While proliferating fibroblasts would be expected to
secrete molecules important for wound healing [15], quiescent
fibroblasts might be expected to secrete extracellular matrix
molecules required at the end of a wound healing process or for
maintenance of quiescent tissue [45]. We monitored the levels of
secreted protein in conditioned medium collected from plates
containing proliferating or CI14 fibroblasts [13]. Because serum
interferes with immunoblotting for specific proteins, these
experiments were performed in no serum and 0.1% serum
conditions. As shown in Figure 9, the levels of fibronectin, collagen
21A1, and laminin alpha 2 in conditioned medium from CI14
fibroblasts was higher than the levels in conditioned medium from
proliferating fibroblasts, thus demonstrating a biosynthetic com-
mitment for contact-inhibited fibroblasts that may contribute to
their high metabolic rate.
Overview of the Metabolic Changes between
Proliferation and Quiescence in Fibroblasts
The metabolic profiles of proliferating and CI14 fibroblasts are
summarized in Figure 3. Fibroblasts in both proliferating and
contact-inhibited states utilize glycolysis extensively. Proliferating
fibroblasts rely on the PPP to generate ribose for nucleotide
biosynthesis and NADPH for biosynthetic purposes. Contact-
inhibited fibroblasts employ the oxidative PPP to generate
NADPH, and the carbon skeletons are largely returned to
glycolysis as glyceraldehyde-3-phosphate and fructose-6-phos-
phate. Fibroblasts in both proliferating and contact-inhibited
states contribute some glucose carbons to the TCA cycle. In
contact-inhibited fibroblasts, carbons contributed by glucose are
transmitted through the TCA cycle; in proliferating fibroblasts,
there is little forward flux between citrate and a-ketoglutarate.
Contact-inhibited fibroblasts rely more heavily on anaplerotic flux
from pyruvate to oxaloacetate via pyruvate carboxylase; prolifer-
ating fibroblasts rely more heavily on glutamine, perhaps because
of their higher demand for nitrogen. Glutamine drives the forward
flux through the TCA cycle and also reverse flux from a-
ketoglutarate to citrate, especially in the contact-inhibited
fibroblasts. This reverse flux provides a mechanism for shuttling
NADPH from mitochondria to the cytosol.
Discussion
What Do Quiescent Fibroblasts Do with All of Their
Energy?
We discovered that fibroblasts induced into quiescence by
contact inhibition maintain a high metabolic rate. In contact-
inhibited fibroblasts, nucleotide biosynthesis is reduced, yet the
rate of glycolytic, PPP, and TCA flux is almost completely
maintained. Even fibroblasts that have been contact-inhibited for
2 wk and starved of serum for the final week show only a 2-fold
reduction in glycolytic flux. Contact-inhibited fibroblasts also
presumably generate substantial energy through the TCA cycle,
where we observed flux of both glucose- and glutamine-derived
carbons through more than a complete cycle. Consistent with
these multiple routes of energy generation, the ATP/AMP ratio is
high in contact-inhibited fibroblasts (Figure S2).
What then do the quiescent fibroblasts do with all of their
energy? Our data suggest three avenues for energy utilization.
First, contact-inhibited fibroblasts may continuously degrade and
resynthesize their macromolecules and membrane components
via increased autophagy [43,44] (E. M. Haley, A. L.-M., and H.
A. C., unpublished observation), a strategy that would help to
ensure that old and potentially damaged macromolecules and
membranes do not accumulate. Our data suggest that contact-
inhibited fibroblasts may degrade protein and fatty acids at an
enhanced rate compared with proliferating fibroblasts. The
conclusion most consistent with our data is that the proliferating
and contact-inhibited fibroblasts synthesize amino acids and fatty
acids at rates that are comparable, with the new biomass
contributing to new cells in proliferating fibroblasts and the new
biomass replacing degraded molecules in the contact-inhibited
fibroblasts.
Second, contact-inhibited and serum-starved fibroblasts induce
pathways that generate NADPH. We discovered that three
NADPH-generating enzymes, G6PD, PGD, and IDH1, are
expressed at higher levels in quiescent than in proliferating
fibroblasts. The results suggest that quiescent fibroblasts activate
an NADPH-generating program of enzyme induction. One role of
the NADPH may be to ensure the availability of GSH and
thioredoxin for the detoxification of free radicals. Indeed, levels of
total free radicals are lower in the contact-inhibited than in
proliferating fibroblasts (E. M. Haley and H. A. C., unpublished
data). Another role for the NADPH generated may be to support
resynthesis of fatty acids, as fatty acid degradation yields NADH
while synthesis requires NADPH.
Third, quiescent fibroblasts may acquire new cell-type-specific
functions. In contrast to lymphocytes, which, with the exception of
plasma cells, lack a major biosynthetic function in their quiescent
state, fibroblasts secrete proteins and other molecules needed for
the extracellular matrix even when they are quiescent. Contact-
inhibited fibroblasts direct some of their metabolic activity toward
this biosynthetic purpose, as we observed elevated levels of specific
extracellular matrix proteins in contact-inhibited compared with
proliferating fibroblasts (Figure 10). Thus, quiescent fibroblasts,
relieved of the biosynthetic requirements associated with creating
progeny, can turn their protein synthesis machinery toward the
synthesis of proteins that are beneficial for the organism as a
whole.
What Is Distinctive about Quiescence?
Our findings shed light on some larger questions about
quiescence: What are the fundamental attributes of a quiescent
state? Is there a single quiescent state or are there multiple
quiescent states? Our results suggest that quiescence is not
necessarily associated with a shutdown of glycolysis, as reported
for lymphocytes and thymocytes [6–10]. Quiescent cells can
actually be highly metabolically active. In this respect, quiescent
fibroblasts resemble terminally differentiated cells like cardiomy-
ocytes, neurons, and renal tubular epithelial cells, which are
among the highest energy consumers in mammals. These
terminally differentiated cells are well-known to employ nutrients
to achieve their contractile, signaling, and transport functions.
Whether their metabolic activity, like that of contact-inhibited
fibroblasts, is also directed to continuously refreshing their protein
and lipid composition merits further study.
In addition to differing from quiescent lymphocytes, different
types of quiescent fibroblasts can vary. While CI7, CI14, and
CI14SS7 fibroblasts are indistinguishable morphologically or by
traditional cell cycle analysis, they differ with regard to their
metabolic profiles. Compared with fibroblasts induced into
quiescence by contact inhibition, fibroblasts also deprived of serum
exhibited a decrease in lactate excretion rates, smaller pool sizes of
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CoA. Our findings suggest that cells of different types may actually
be in distinct quiescent states, and may have discovered distinct
solutions to the metabolic challenges associated with quiescence.
Finally, our findings suggest that contact-inhibited and serum-
starved fibroblasts are particularly susceptible to apoptosis induced
by treatment with DHEA, a pentose phosphate pathway inhibitor.
The ability to selectively kill quiescent cells could have therapeutic
potential [46,47]. For instance, tumor stem cells may exist in a
quiescent state for years, while retaining the capacity to emerge
from dormancy, proliferate, and initiate a tumor recurrence. Small
molecules that target the pathways invoked by these cells to
facilitate their survival during dormancy could be useful additions
to our therapeutic arsenal. We discovered that contact-inhibited
and serum-starved fibroblasts rely on the PPP and possibly other
NADPH-generating reactions for viability. Small molecule
inhibitors like DHEA might ultimately prove valuable for targeting
quiescent tumor cells.
Materials and Methods
Tissue Culture
Primary human fibroblasts were isolated from foreskin as
previously described (see Supplemental Data in [48]). Fibroblasts
were maintained in DMEM (Hyclone, Thermo Fisher Scientific)
supplemented with 10% fetal bovine serum (Hyclone) and
100 mg/ml penicillin and streptomycin (Invitrogen). Cells were
collected while proliferating, after 1 wk of confluent maintenance
(CI7), after 2 wk of confluent maintenance (CI14), after 2 wk of
maintenance with the last 7 d in 0.1% serum (CI14SS7), and after
serum starvation in 0.1% serum for 3 d, 4 d (SS4), or 7 d (SS7).
Cells made quiescent by serum starvation alone were plated
sufficiently sparsely so that they did not contact surrounding cells.
Medium was changed every 2 d. Proliferating cells were sampled
the day after seeding. In order to better simulate conditions in
vivo, we also used low glucose/low glutamine conditions in which
the glucose level was 1 g/l and the glutamine level was 0.7 mM,
compared with a glucose level of 4.5 g/l and a glutamine level of
4 mM in standard DMEM. While cells were confluent, the
medium was changed regularly. For analysis, cells were transferred
to DMEM (Invitrogen) with 7.5% dialyzed fetal bovine serum
(Atlanta Biologicals or Hyclone) the day before the experiment.
Fibroblasts were photographed through a Nikon Eclipse TS100
microscope using a Scion 8-bit color firewire 1394 digital camera.
Images were captured with Scion VisiCapture software (Scion).
Flow Cytometry for Cell Cycle
Cells were trypsinized and collected into phosphate-buffered
saline (PBS) containing 5% bovine growth serum (Hyclone). Cells
were pelleted, resuspended in 67% ethanol in PBS, and stored at
4uC. For flow cytometry, cells were pelleted, washed with PBS,
and resuspended in PBS with PI (40 mg/ml) (VWR) and RNAse A
(200 mg/ml) (Thermo Fisher Scientific). Samples were incubated
in the dark for 1 h at room temperature, and analyzed using a
FACSort flow cytometer (BD Biosciences). The PI was excited at
488 nm, and emitted fluorescence was collected on detector FL2
with a bandpass filter of 585/42 nm. At least 20,000 cells were
collected and analyzed with CellQuest software (BD Biosciences).
Cell cycle distributions were calculated with ModFit LT software
using the Watson Pragmatics algorithm.
Flow Cytometry Analysis for Pyronin Y
To differentiate cells in G0 versus G1, fibroblasts representing
each quiescence condition were trypsinized and suspended in cold
Hank’s buffered saline solution at a concentration of 2610
6 cells/
ml, then added to a fixative of ice-cold 70% ethanol. Cells were
fixed for at least 2 h, washed, and resuspended at 4610
6 cells/ml.
A solution of 4 mg/ml pyronin Y and 2 mg/ml Hoechst 33342 was
added to the cell suspension and incubated on ice for 20 min
before measuring cell cycle status by flow cytometry. To determine
RNA content, pyronin Y was excited at 488 nm and emission was
measured at 562–588 nm. DNA content was determined by
Hoechst 33342. Excitation was measured at 355 nm and emission
was measured at 425–475 nm. Cells in G0 were identified as the
population with 2N DNA content and an RNA content lower than
the level in S phase [49].
Protein Content and Immunoblot Analysis of
Proliferating and Quiescent Fibroblasts for p27
Kip1, IDH1,
G6PD, and PGD Levels
Cells were made quiescent by contact inhibition, serum
starvation, or a combination as indicated in the text or figure,
and collected at the indicated times. The cells were lysed in RIPA
buffer (50 mM Tris-Cl [pH 7.4], 150 mM NaCl, 1% Triton X-
100, 1% sodium deoxycholate, and 0.1% SDS) containing
protease and phosphatase inhibitors (10 mM NaPO4 [pH 7.2],
0.3 M NaCl, 0.1% SDS, 1% NP40, 1% Na deooxycholate, 2 mM
EDTA, protease inhibitor cocktail [Roche, Basel, Switzerland]
and Halt Phosphatase inhibitors [Thermo Fisher Scientific]).
Lysates were sonicated with five pulses for 15 s each at 60 J/W.
Lysates were then incubated for 30 min on ice with periodic
Figure 10. Contact-inhibited fibroblasts secrete high levels of
specific extracellular matrix proteins. Conditioned medium (4 d)
was collected from proliferating (P) and CI14 fibroblasts conditioned
with either no serum or 0.1% serum, and with 0.03% platelet-derived
growth factor (PDGF-BB) for proliferating cells. The amount of
conditioned medium was normalized to the change in protein content
over time. Conditioned medium was precipitated and immunoblotted
with an antibody to fibronectin, collagen (col21a1), or laminin (lama2).
doi:10.1371/journal.pbio.1000514.g010
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10,000 rpm. Total protein amount was assessed by the Lowry
method using the Bio-Rad DC Protein Assay Kit II (Bio-Rad) as
described by the manufacturer. Spectrophotometer readings taken
at 650 nm were compared against a standard curve to determine
lysate concentration. Total protein content was determined as the
product of lysate concentration and lysate volume. Equal amounts
of total cellular proteins were resolved on 12% SDS-PAGE and
electro-transferred onto a PVDF membrane. Membranes were
blocked for 1 h at room temperature in Tris-buffered saline
containing 0.1% Tween-20 (TBS-T) (10 mM Tris [pH 7.6],
15 mM NaCl, and 0.1% Tween-20) or phosphate-buffered saline
containing 0.1% Tween-20 (PBS-T) containing 5% nonfat dried
milk. Membranes were incubated with antibodies to p27 (1:500
diluted in TBS-T/5% milk) (Santa Cruz Biotechnology), IDH1 (1
mg/ml diluted in PBS-T/1% milk) (Lifespan Biosciences), G6PD
(1:1,500 diluted in PBS-T/1% milk) (Novus Biologicals), or PGD
(1:1,000 diluted in PBS-T/1% milk) (GeneTex) overnight.
Following incubation, the membranes were washed three times
in TBS-T or PBS-T and incubated for 1 h with horseradish
peroxidase–conjugated anti-rabbit secondary antibody (1:3,000
diluted into TBS-T/5% milk for p27 or 1:10,000 diluted in PBS-
T/1% milk for IDH1 and G6PD) (GE Healthcare). The
membranes were washed three times with TBS-T or PBS-T,
and immunoreactive bands were detected with an enhanced
chemiluminescence kit (Pierce, Thermo Scientific). The mem-
branes were stripped using Restore Western Blot Stripping Buffer
(Thermo Scientific) according to the manufacturer’s instructions
and immunoblotted with GAPDH (Abcam) (1:5,000 dilution) in
PBS-T/1% milk or TBS-T/5% milk as a loading control.
Intracellular Metabolite Analysis
Highly parallel measurement of intracellular metabolites was
performed as previously described [21]. Metabolites were
extracted from proliferating, CI7, CI14, or CI14SS7 cells by
aspirating the medium from the plate and flash-quenching
metabolic activity with 80% methanol maintained at 280uC.
Cells were incubated in methanol for 15 min, scraped on dry ice,
and pelleted with centrifugation at 4,400 rpm for 5 min. Samples
were re-extracted twice with 80% methanol on dry ice. The three
extractions were pooled and dried under nitrogen gas, dissolved in
300 ml of 50% methanol, and spun at 13,0006 g for 5 min.
Methanol supernatant was then passed through an aminopropyl
column [50]. Eluate from the column was analyzed with positive
ion mass spectrometry via a Finnigan TXQ Quantum Ultra triple-
quadrupole mass spectrometer equipped with an electrospray
ionization source (Thermo Fisher Scientific) [22]. A TSQ
Quantum Discovery MAX mass spectrometer, also equipped with
an electrospray ionization source, was used to collect data on
negative mode ions after separation on a 25-cm C18 column
coupled with a tributylamine ion pairing agent to aid in the
retention of polar compounds [51,52].
To quantify metabolites, peak heights were initially assigned
using XCalibur software (Thermo Fisher Scientific) and then
evaluated manually. Metabolites enriched at least 5-fold in a
sample compared with a control plate containing only medium
were retained in the analysis. Of the 172 metabolites monitored,
62 met these criteria. Signals that were below the limit of detection
were assigned 100. Metabolite levels were normalized by the
amount of protein present.
Metabolic Flux Analysis
To monitor the flux through metabolic pathways, samples were
incubated with medium containing isotope-labeled nutrient for
different amounts of time. Dulbecco’s medium lacking glucose and
glutamine was isotope-labeled by adding back glucose or
glutamine ([U-
13C]-glucose, [1, 2-
13C]-glucose, [3-
13C]-glucose,
or [U-
13C]-glutamine; Cambridge Isotope Laboratories) to a final
concentration of 4.5 g/l glucose or 0.584 g/l glutamine. Samples
were taken at the indicated time points after medium change and
processed as described above. Levels of
12C and
13C forms of
metabolic intermediates were monitored with LC-MS/MS [53].
Metabolite Uptake and Excretion
Medium was sampled from cells under a variety of conditions:
proliferating, CI7, CI14, CI14SS7, SS4, SS7, low glucose/low
glutamine proliferating, and low glucose/low glutamine CI14.
Conditioned medium was sampled over a time course from 0 to
96 h for fibroblasts, depending upon the experiment. The levels of
glucose, lactate, glutamine, and glutamate were measured using a
YSI 7100 Select Biochemistry Analyzer (YSI Incorporated). The
rate of glucose consumption, lactate excretion, glutamine con-
sumption, and glutamate excretion was determined as the rate that
these metabolites appeared or disappeared from the medium
divided by the time integral of the protein mass of cells on the plate
during that time period.
Glutathione Measurement
The total GSH and GSSG content of proliferating, CI7, CI14,
and CI14SS7 fibroblasts were determined using Cayman Chem-
ical’s Glutathione Assay Kit according to the manufacturer’s
instructions (Cayman Chemical). Cayman’s GSH assay kit employs
acarefullyoptimizedenzymaticrecyclingmethod,usingglutathione
reductase for the quantification of GSH. Briefly, cells were
harvested using a cell lifter in 1.5 ml of cold buffer (i.e., 50 mM
MES or phosphate buffer [pH 6–7] containing 1 mM EDTA) and
were centrifuged at 10,0006 g for 15 min at 4uC, followed by
metaphosphoric acid deproteinization and addition of triethanol-
amine solution. Half of the samples were then treated with 2-
vinylpyridine to allow quantification of the GSSG pool exclusively.
Assay Cocktail (a mixture of 2-(N-morpholino) ethanesulfonic acid
Buffer [11.25 ml], reconstituted Cofactor Mixture [0.45 ml],
reconstituted Enzyme Mixture [2.1 ml], water [2.3 ml], and
reconstituted 5,59-dithiobis-(2-nitrobenzoic acid) [0.45 ml]) was
added, and total GSH and GSSG in the deproteinated samples
were measured at 405 nm in a spectrophotometer. GSH concen-
tration of the samples was determined by the endpoint method and
expressed in micromolar concentrations.
PPP Inhibition and PI Live/Dead Analysis
Proliferating and CI14 fibroblasts were treated with DHEA
dissolved in ethanol or dimethylsufoxide (0.1% vol/vol) for 4 d.
On the fourth day of treatment with the inhibitor, cells were
trypsinized and collected into conditioned medium. Cells were
then centrifuged for 5 min at 1,000 rpm. The supernatant was
aspirated and cells were taken up in PBS with 1 mg/ml PI (VWR).
Cells were kept on ice and immediately analyzed by flow
cytometry using a BD LSRII multi-laser analyzer (BD Bioscienc-
es). PI was excited at 488 nm, and emitted fluorescence was
collected through a 610/20 bandpass filter. At least 40,000 cells
were collected and analyzed with FACSDiVa software (BD
Biosciences). PI-negative cells were counted as live cells, and PI-
positive cells were counted as dead cells.
PPP Inhibition and Apoptosis Analysis
Apoptosis was measured based on the levels of caspase-3/7
released into the medium using the ApoTox-Glo Triplex Assay
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plated in triplicate at 10,000 cells per well in white-walled, clear-
bottom 96-well plates (Costar, Corning Life Sciences). For contact
inhibition, cells were plated 7 d prior to the start of treatment; for
serum starvation, cells were plated 4 d prior to treatment and
switched to 0.1% serum medium for the remaining 3 d;
proliferating cells were plated the day prior to the start of
treatment. Increasing concentrations of DHEA or ethanol vehicle
alone were added to the medium in each well, and treatment
proceeded for 4 d. Cells in serum starvation conditions were
incubated in 0.1% serum during treatment as well. The apoptosis
reagent was added at 100 ml per well and incubated for 1 h prior
to reading. Luminescence was read from the top using a Synergy-2
plate reader (Biotek). Luminescence data were normalized to the
vehicle only condition.
Measurement of Carbon Incorporation into Fatty Acids
Lipid synthesis from glutamine was measured using a modified
version of a previously published protocol [53]. Briefly, prolifer-
ating, CI7, CI14, and CI14SS7 fibroblasts were incubated in
medium containing 5 mCi/ml [U-
14C]-glutamine at 4 mM (0.4%
labeled). After incubation for 24 h, the culture medium was
aspirated, cells were washed with PBS, and phospholipids were
extracted by addition of 500 ml of 3:2 hexane:isopropanol. The
culture dishes were then washed with an additional 500 ml of the
hexane:isopropanol mixture. The resulting total extract was dried
using a speed-vac, resuspended in 500 ml of 1 N KOH in 90:10
methanol:water, and incubated at 70uC for 60 min to saponify
lipids. Sulfuric acid (100 ml, 2.5 M) was then added, followed by
hexane (700 ml) to extract the saponified fatty acids. The organic
and aqueous phases were separated by centrifugation and
scintillation-counted.
Microarray Analysis
To monitor gene expression levels, proliferating, CI7, or CI14
fibroblasts were trypsinized, removed from the plate, pelleted, and
stored at 280uC. Total RNA was isolated using the mirVana
miRNA Isolation kit (Ambion) according to the manufacturer’s
instructions. RNA quality was verified using a Bioanalyzer 2100
(Agilent Technology), and the amount was determined with a
NanoDrop spectrophotometer (NanoDrop Technologies). Total
RNA (325 ng) was amplified using the Low RNA Input
Fluorescent Labeling Kit (Agilent Technologies) according to the
manufacturer’s protocol. Cy-3 (PerkinElmer) was directly incor-
porated into the cRNA from proliferating cells during in vitro
transcription. Cy-5 was incorporated into complementary RNA
from CI7 or CI14 fibroblasts. Mixtures of Cy-3-labeled and Cy-5-
labeled cRNA were co-hybridized to Whole Human Genome
Oligo Microarray slides (Agilent Technologies) at 60uC for 17 h
and subsequently washed according to the Agilent Technologies
standard hybridization protocol. Slides were scanned with a dual
laser scanner (Agilent Technologies). Images were monitored for
quality control. The Agilent Technologies feature extraction
software, in conjunction with the Princeton University MicroArray
database (http://puma.princeton.edu/), was used to compute the
log ratio of the two samples for each gene after background
subtraction and dye normalization. The entire experiment was
performed twice.
Analysis of Extracellular Matrix Protein Levels in
Conditioned Medium
For the analysis of extracellular matrix proteins in conditioned
medium, we could not perform the experiments in the presence
of high amounts of serum because serum inhibited protein
transfer after immunoblotting. As previously described [13],
proliferating fibroblasts were conditioned at low cell density in the
presence of platelet-derived growth factor with either no serum or
0.1% serum. Quiescent fibroblasts were cultured at high density
in the absence of platelet-derived growth factor with either no
serum or 0.1% serum. Medium was conditioned over 4 d and
during that time, protein lysates were collected over a time
course. The protein content of the cell lysates was plotted against
the time of lysate collection. A curve that fit the data was
generated and the area under the curve, the integrated protein–
hour quantity, was divided by the volume of medium collected
from the proliferating or quiescent plate. The total protein–hour/
volume for each sample was used to adjust the volume of
conditioned medium, which was then mixed with 25% volume of
trichloroacetic acid (Sigma-Aldrich) containing 0.1% sodium
deoxycholate (Sigma-Aldrich), and incubated for 30 min on ice.
Following centrifugation, samples were washed 3–4 times with
220uC acetone, resuspended in sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis sample buffer and separated under
reducing conditions on 5% (for fibronectin and COL21A1) or
12% (for LAMA2) sodium dodecyl sulfate-polyacrylamide gels.
Proteins were transferred for 1 h at 100 V to Westran
polyvinylidene fluoride membranes (PerkinElmer). Membranes
were blocked for 1 h at room temperature in 5% nonfat dried
milk in PBS-T. Membranes were then incubated overnight at
4uC with a mouse monoclonal anti-fibronectin clone HFN7.1
(1:2,000 dilution, generous gift of Jean Schwarzbauer, Princeton
University), mouse polyclonal antibody against COL21A1 (1:750
dilution, Abcam), or mouse monoclonal antibody against
LAMA2 (3 mg/ml, Abnova) diluted in PBS-T/1% milk. Follow-
ing overnight incubation in the primary antibody, membranes
were washed three times in PBS-T, incubated for 1 h in a
1:10,000 dilution of horseradish peroxidase–conjugated sheep
anti-mouse secondary antibody (GE Healthcare) in PBS-T/1%
milk. Membranes were exposed to X-ray film, and film was
scanned with a Hewlett-Packard Scanjet 4890 using Hewlett-
Packard software. The intensity of individual bands was
determined with ImageJ analysis software.
Computational Determination of Fluxes
Fluxes were determined by integration of all available forms of
experimental data within a quantitative flux-balanced framework
using the same strategy as described in Munger et al. [53]. An
ODE model (Figure S3) of central carbon metabolism was
constructed. The model assumes steady-state, mass-balanced flux
and simulates the resulting labeling dynamics after switching cells
from unlabeled medium to uniformly
13C-labeled glucose or
glutamine. The model consists of 55 ODEs, describing the rate of
loss of unlabeled metabolites and the rate of accumulation of
labeled metabolites. It builds upon the previously described model
[53] with a few changes. An exchange flux (F12) was introduced in
glycolysis between DHAP and FBP. Backward flux (F11) from a-
ketoglutarate to citrate, together with a latent citrate pool that is
never labeled (determined by the lowest unlabeled citrate pool size
observed in all experiments), was introduced in the TCA cycle.
The latent citrate pool was added because for citrate, but not other
metabolites, a substantial fraction of the pool (approximately 40%
for the proliferating cells) did not label over the course of the
experiment. Beyond labeling dynamics, additional input data
included metabolite levels, rates of metabolite consumption and
excretion, and the glycolysis–PPP flux convergence ratio deter-
mined after feeding [1, 2-
13C]-glucose for 2 h. Model parameters
(fluxes, as well as pool sizes of a small number of metabolites that
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a genetic algorithm that minimizes a cost function defined as the
sum of weighted differences between the experimental data and
computational results (Table S3) [54]. As a global search
algorithm, the genetic algorithm computationally probes for
alternative flux solutions consistent with the experimental results.
For each cell type, the algorithm was run until 1,000 consistent
solutions (i.e., parameter sets that produced the lowest cost values
when the algorithm reached convergence) were obtained. The
distribution of the 1,000 values was then used to quantitatively
represent each identified parameter. Since the distributions are not
Gaussian, a flux is considered quantitatively different between
proliferating and quiescent cells only when the distributions from
the proliferating and quiescent fibroblasts do not overlap. This
measure minimizes the false positives that may occur when only
one or a few solutions are identified [54]. Although qualitatively
supportive of the model-inferred enhancement of anapleurotic flux
from glucose in quiescent fibroblasts, labeling data for [3-
13C]-
glucose, which was taken at 8 h, were quantitatively inconsistent
with the other labeling data, which covered the first 2 h of
incubation only. The [3-
13C]-glucose data were accordingly
excluded from the computational analysis. The computer code is
available upon request.
Accession Numbers
The Entrez Gene (http://www.ncbi.nlm.nih.gov/gene) acces-
sion numbers for the proteins discussed in this paper are G6PD,
2539; IDH1, 3417; IDH2, 3418; and PGD, 5226.
Supporting Information
Figure S1 Glycolytic rates in proliferating and quies-
cent fibroblasts. (A) Rates of glucose consumption, lactate
excretion, glutamine consumption, and glutamate excretion were
monitored in proliferating, CI7, CI14, CI14SS7, SS4, SS7,
proliferating low glucose/low glutamine, and CI14 low glucose/
low glutamine fibroblasts using the YSI 7100 bioanalyzer. Levels
were normalized for the amount of cellular protein present during
the conditioning time. Error bars indicate standard error. (B–E)
Representative plots of metabolite levels over time used to
determine the reported rates.
Found at: doi:10.1371/journal.pbio.1000514.s001 (7.08 MB PDF)
Figure S2 Basal metabolites in proliferating, CI7, and
CI14 fibroblasts. Metabolites were analyzed using LC-MS/
MS. Individual metabolite levels were normalized for protein
content. The log (base 2) of the ratio of CI7 or CI14 to the
average proliferating metabolite levels over all experiments was
determined for each sample. Means from four experiments each
containing 4–5 replicates are shown. Error bars indicate standard
error.
Found at: doi:10.1371/journal.pbio.1000514.s002 (0.59 MB TIF)
Figure S3 Flux-balanced model of central carbon me-
tabolism. An ODE-based model of central carbon metabolism
was developed to describe the time-dependent metabolic labeling.
(A) Schematic of fluxes in the model. F0–F12 represent the
unknown fluxes, except for F9, which is the latent hexose–
phosphate pool. A, B, C, and D are the uptake and excretion rates.
X, Y, and Z are dependent parameters of the above fluxes and pool
sizes, whose expressions are determined by balancing all the
relevant fluxes. X is the protein synthesis rate, Y is the anaplerotic
flux from pyruvate, and Z is the net flux from malate to
oxaloacetate. (B) Conversion of the isotopically labeled metabolic
forms in the glucose and glutamine labeling experiments. The
numbers under the metabolite names represent the positions at
which a metabolite is labeled (‘‘0’’ means an unlabeled metabolite).
Low-abundance isotope-labeled forms, such as 16
13C-citrate,
were excluded from the model.
Found at: doi:10.1371/journal.pbio.1000514.s003 (1.15 MB TIF)
Figure S4 Modeling results for central carbon metabo-
lism. (A) Model fits for metabolites in proliferating, CI7, CI14,
and CI14SS7 fibroblasts. Experimentally measured concentrations
of different labeled and unlabeled metabolites (mean 6 one
standard deviation) at the indicated time points are plotted against
the model predictions (smooth curves) from a typical flux solution
set. The time axis is in logarithmic scale to better illustrate the
samples at early time points. Data and simulated results for
[U-
13C]-glucose labeling experiments are labeled by the metab-
olite name only. For the [U-
13C]-glutamine labeling, a ‘‘Q’’
precedes the metabolite name. (B) Histogram of the distribution of
consistent fluxes in each condition. The x-axis indicates the flux
values (in logarithmic scale); the y-axis is the number of counts
(within the 1,000 consistent solution sets) that have a specific flux
value. The resultant solution distribution provides a representation
of the fluxes that are potentially consistent with the observed
laboratory data in each cell state.
Found at: doi:10.1371/journal.pbio.1000514.s004 (0.43 MB TIF)
Table S1 Absolute fluxes in proliferating and quiescent
fibroblasts. For each identified flux, the median value of its
distribution (A) and the best value (i.e., the one that resulted in the
best match between the experimental data and computational
simulations) (B) are reported. Flux values that are statistically
higher in quiescent than proliferating conditions (i.e., their
distributions do not overlap) are highlighted in red, while the
fluxes that are lower in quiescent than proliferating conditions are
highlighted in blue.
Found at: doi:10.1371/journal.pbio.1000514.s005 (0.07 MB
DOC)
Table S2 Malate and citrate labeling after incubation
with [3-
13C]-glucose in proliferating, CI7, CI14, and
CI14SS7 fibroblasts.
Found at: doi:10.1371/journal.pbio.1000514.s006 (0.01 MB XLS)
Table S3 Functional forms of the components of the
cost function for the genetic algorithm. The expression for
the total cost is
J~
1
5
X 5
n~1
JnzJ6 ð1Þ
The best possible cost value is 1, when the model results fit all
experimental data perfectly.
Found at: doi:10.1371/journal.pbio.1000514.s007 (0.06 MB
DOC)
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